Tevard Biosciences Reports Full Dystrophin Restoration and Titin Rescue with Suppressor tRNA Therapy at ASGCT 2026
Tevard Biosciences presented preclinical data showing its suppressor tRNA therapy achieved complete dystrophin restoration in Duchenne muscular dystrophy models and robust titin rescue in cardiomyopathy models, highlighting the platform's potential for treating nonsense mutation diseases.
Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies for genetic diseases, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston. The data demonstrate that the company's next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, the sup-tRNAs provided durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
The findings, announced in a press release, underscore the potential of Tevard's platform to address the underlying genetic cause of these devastating diseases. In DMD models, the sup-tRNAs achieved approximately 100% restoration of full-length dystrophin, a protein essential for muscle integrity. For DCM-TTNtv, the therapy restored full-length titin, a giant protein critical for heart muscle function. The data suggest that the sup-tRNA approach can provide durable, cell-specific expression of native proteins, offering a potential one-time treatment for patients with nonsense mutations.
Tevard's compact tRNA architecture enables flexible packaging into adeno-associated virus (AAV) vectors, allowing precise dose control and broad applicability across different genetic diseases. The platform is designed to suppress premature termination codons, allowing the cellular machinery to read through nonsense mutations and produce full-length, functional proteins. This mechanism differs from other gene therapies that deliver exogenous genes or edit DNA, as it leverages the cell's own translational machinery to restore endogenous protein expression.
The implications of these results are significant for the approximately 10% of genetic diseases caused by nonsense mutations, including many forms of muscular dystrophy and cardiomyopathy. Current treatments for DMD, such as corticosteroids and exon-skipping therapies, offer limited benefit and do not address the root cause. Similarly, for DCM-TTNtv, there are no approved therapies targeting the underlying genetic defect. Tevard's sup-tRNA therapy could potentially provide a universal approach for nonsense mutations, regardless of the specific gene involved.
The company is advancing programs in muscular dystrophies, heart disease, and neurological disorders. For more information, visit www.tevard.com. The full announcement, including downloadable images and bios, can be accessed here.